Physician profile
Xueming Ye
NPI 1427088566
$490.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $91.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $101.82 | 2019-2020 | |
| Shire North American Group INC | $72.05 | 2019 | |
| Ironshore Pharmaceuticals INC. | $70.28 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $63.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.24 | 2019-2020 | |
| Lundbeck LLC | $22.87 | 2019-2020 | |
| Indivior INC. | $15.28 | 2019 | |
| Allergan, INC. | $14.85 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.80 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.77 | 2019 | |
| Kaleo, INC. | $14.50 | 2019 | |
| Adlon Therapeutics L.P. | $12.29 | 2019 | |
| Neos Therapeutics, LP | $11.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xueming Ye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.